NCT01955629View on ClinicalTrials.gov

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Aflibercept AVE0005

Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

DRUG

Oxaliplatin

Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

DRUG

Capecitabine

Pharmaceutical form: Tablets; Route of administration: Oral

Trial Locations (2)

16132

Investigational Site Number 380-001, Genova

Unknown

Investigational Site Number 380-002, Milan

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

collaborator

Regeneron Pharmaceuticals

INDUSTRY

NCT01955629 - Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient | Biotech Hunter | Biotech Hunter